NCT02530138 - Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Streptococcus thermophilus vs Placebo & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Background

Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) is recognized as the primary cause of liver disorders globally. Despite its prevalence, there is currently no established treatment for NAFLD patients who have a normal or low body mass index (BMI). This study aimed to assess the effectiveness of synbiotics supplementation in treating NAFLD patients within this BMI category.
Mofidi et al. 2017 Br J Nutr 117(5): 662-668

Study overview

NCT02530138 - Synbiotic vs Placebo & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) is a randomized, double-blind, placebo-controlled clinical phase II…